跳转至内容
Merck

SML2804

Sigma-Aldrich

达格列净

≥98% (HPLC), powder, SGLT2 inhibitor

别名:

(1S)-1,5-酐-1-C-[4-氯-3-[(4-乙氧基苯基)甲基]苯基]-D-葡萄糖醇, BMS 512148, BMS-512148, (2S,3R,4R,5S,6R)-2-(3-(4-乙氧基苄基)-4-氯苯基)-6-羟甲基-四氢-2H-吡喃-3,4,5-三醇

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H25ClO6
分子量:
408.87
MDL號碼:
分類程式碼代碼:
51111800
NACRES:
NA.77

product name

达格列净, ≥98% (HPLC)

品質等級

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D (+7.0° to +13.0°, c = 0.2 in methanol)

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

CCOC1=CC=C(C=C1)CC2=C(C=CC([C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)=C2)Cl

InChI

1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1

InChI 密鑰

JVHXJTBJCFBINQ-ADAARDCZSA-N

生化/生理作用

达格列净(BMS-512148)是一种口服活性、有效和选择性的肾钠依赖性葡萄糖共转运蛋白2(SGLT2;SLC5A2)抑制剂(人/大鼠SGLT2 IC50 = 1.1/3 nM,而人/大鼠SGLT1 IC50 = 1.39/0.6 μM;R-甲基-D-吡喃葡萄糖苷(AMG)摄取测定以及相应的CHO转染子)。达格列净通过防止肾脏葡萄糖重吸收过程并促进尿液中葡萄糖排泄,具有良好的药代动力学特性和口服利用度(口服1 mg/kg和6.6 mg/kg后,在大鼠和狗中分别降低了84%和83%),从而降低了血糖水平(在链脲佐菌素(STZ)诱导的高血糖大鼠中,在口服0.1 mg/kg后5小时降低了55%)体内

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - STOT RE 1

標靶器官

Kidney

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Wei Meng et al.
Journal of medicinal chemistry, 51(5), 1145-1149 (2008-02-12)
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME
Dapagliflozin - a breakthrough in the search for drugs to treat HFrEF.
Karina Huynh
Nature reviews. Cardiology, 16(12), 700-700 (2019-10-04)
Ryo Shibusawa et al.
Scientific reports, 9(1), 9887-9887 (2019-07-10)
The new type 2 diabetes drug, dapagliflozin, reduces blood glucose levels and body weight by inhibiting sodium glucose transporter 2 (SGLT2) in proximal tubular cells. SGLT2 inhibitors might modulate glucose influx into renal tubular cells, thereby regulating the metabolic conditions
Kazuno Omori et al.
Metabolism: clinical and experimental, 98, 27-36 (2019-06-17)
To explore the beneficial effects of dapagliflozin and/or insulin glargine on the pancreatic beta cell mass and hepatic steatosis in db/db mice. Six-week-old db/db mice were assigned to one of four groups: untreated (Placebo), treated with dapagliflozin (Dapa), treated with
Ying-Ying Chen et al.
International journal of molecular sciences, 20(18) (2019-09-08)
Cataracts in patients with diabetes mellitus (DM) are a major cause of blindness in developed and developing countries. This study aims to examine whether the generation of reactive oxygen species (ROS) via the increased expression of glucose transporters (GLUTs) and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门